CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
FDA Approves Itovebi (Itovebi) for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
FDA approves new breast cancer drug Itovebi for a specific type of advanced cancer.
The FDA approved Itovebi in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, H…
A new oral drug, Itovebi, is now FDA-approved for advanced breast cancer with a specific genetic mutation, offering another option when horm…
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer.
New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer.
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.